The number of domestically-developed new drugs approved for marketing has been creeping up each year, the conference heard. Photo: Shutterstock
Reform has unleashed Chinese drugs innovation boom, though some pharma firms may not survive under intense price pressure, industry leaders say
- Sales of newly developed medicines, or novel drugs, could more than triple to 960 billion yuan in the eight years to 2025, according to forecasts
- Price pressure could spell the end for drug makers that fail to innovate, an industry conference hears
Follow your favourite topic and get notified
The number of domestically-developed new drugs approved for marketing has been creeping up each year, the conference heard. Photo: Shutterstock
Corrected [11:58am, 15 Jan, 2021]
- [11:58am, 15 Jan, 2021]
Corrects insurance claims amount to 1.85 trillion yuan in third paragraph from the end
We are part of the Trust Project What is it?
